09:26:06 PM

ANPC Stock News

ANPC - AnPac Bio-Medical Science Co Ltd

08/05/22 4:45 PM

Nasdaq : ANPC

managementlow float

AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that effective August 2, 2022, the

RHEA-AI

neutral

07/18/22 6:39 PM

Nasdaq : ANPC

low float

AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees

RHEA-AI

neutral

06/10/22 7:30 AM

Nasdaq : ANPC

low float

AnPac Bio Regains Compliance with Requirements to Remain Listed on Nasdaq Capital Market

RHEA-AI

neutral

05/31/22 5:00 PM

Nasdaq : ANPC

earningslow float

AnPac Bio Reports 49.1% Decrease in Net Loss in First Quarter of Fiscal 2022

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the first quarter ended March 31,

RHEA-AI

neutral

05/16/22 5:00 PM

Nasdaq : ANPC

earningslow float

AnPac Bio Reports Fiscal Year 2021 Annual Financial Results

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its annual financial results for the year ended December 31, 2021.

RHEA-AI

positive

05/11/22 7:30 AM

Nasdaq : ANPC

low float

AnPac Bio Regains Compliance with Market-Value-Of-Publicly Held Shares Requirement upon Transfer to The Nasdaq Capital Market

RHEA-AI

neutral

05/06/22 7:30 AM

Nasdaq : ANPC

low float

Nasdaq Hearing Panel Grants AnPac Bio’s Request to Transfer Securities from The Nasdaq Global Market to The Nasdaq Capital Market

RHEA-AI

very positive

04/11/22 7:30 AM

Nasdaq : ANPC

low float

AnPac Bio and New Investor Sign Equity Investment Totaling $15 Million

RHEA-AI

neutral

04/08/22 9:12 PM

Nasdaq : ANPC

managementlow float

AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board Member

RHEA-AI

neutral

04/04/22 7:30 AM

Nasdaq : ANPC

low float

AnPac Bio Filed Request for a Hearing Regarding Continued Listing on NASDAQ, The Hearing was Granted and scheduled for Late April

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

ANPC Data

IndustryMedical Laboratories
Websitewww.anpacbio.com
Security nameAnPac Bio-Medical Science Co Ltd - ADR
Issue typead
SectorHealth Care and Social Assistance
Sic code8071
Employees2021
Tags
- Health Technology
- Biotechnology
- Health Care and Social Assistance
- Medical Laboratories
AddressC/O SHRM Trustees (BVI) Limited
StateRoad Town
CityPo Box 4301 Trinity Chambers
ZipTORTOLA
CountryBritish Virgin Islands

About AnPac Bio-Medical Science Co Ltd

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 128 issued patents as of June 30, 2020. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 31, 2019. AnPac Bio's CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.